GHRS - GH Research - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

195.1M

Cash

165.4M

Avg Qtr Burn

-7.456M

Short % of Float

9.21%

Insider Ownership

40.39%

Institutional Own.

58.06%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Postpartum depression, Bipolar depression	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH002 (IV mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GH001 (inhalable mebufotenin) (5-MeO-DMT) Details Treatment Resistant Depression	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.